← Issue №18/ week of Nov 1, 2026/Hepatology

Serum Hepatocyte Growth Factor Predicts Outcomes in Non-Acetaminophen Drug-Induced Acute Liver Failure.

From GI Signals issue №18: what this paper found, what it changes, and where it sits against the current standard of care, reviewed by Simon Mathews, MD.

Hepatology prospective cohort · n=79 · Nov 1, 2026 · Liver International · IF 6.7

Serum Hepatocyte Growth Factor Predicts Outcomes in Non-Acetaminophen Drug-Induced Acute Liver Failure.

Diagnosticacute liver failurebiomarkerbasic sciencetranslational
Clinical takeawayNo clinical action yet: HGF is a prognostic biomarker in non-APAP-DILI-ALI/ALF, but its clinical utility requires validation in a prospective cohort.
What it foundHGF levels were markedly elevated in non-APAP-DILI-ALI/ALF patients (5070 ± 4001 pg/mL vs. 276 ± 581 pg/mL in healthy donors) and highest in those who died or underwent transplantation (6421 ± 4359 pg/mL vs. 4102 ± 3456 pg/mL; p = 0.009).
ContextChallenges current reliance on MELD score by suggesting HGF may improve risk stratification in non-APAP-DILI-ALF, particularly in the ALF subgroup (AUC 0.811 vs. 0.643 for MELD).
Emergingsuggested applicable standard· American Association for the Study of Liver Diseases (AASLD), "AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury" (Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V), Hepatology, 2023 (Guidance Statement 13)

No single passage of this standard matched the paper closely enough to quote, so none is shown. The standard is cited above.

Our full summary of this standard

Initiate the DILI evaluation only for clinically significant liver injury, serum AST or ALT > 5× ULN, or ALP > 2× ULN (or the pretreatment baseline if that value is abnormal) on two separate occasions; total serum bilirubin > 2.5 mg/dL with an elevated AST, ALT or ALP; or INR > 1.5 with an elevated AST, ALT or ALP, not for any minor liver-test abnormality (GS 13). In a patient with new liver test abnormalities after drug, herbal or dietary supplement (HDS) exposure, take a detailed medication and HDS history including intravenous agents such as monoclonal antibodies; most hepatotoxic drugs cause injury within the first 6 months, though some agents have longer latency and hypersensitivity reactions may appear within 24-72 hours (GS 14). Treat DILI as a diagnosis of exclusion: test for hepatitis A IgM, HBsAg, anti-HBc IgM and HCV RNA, obtain autoantibodies (ANA, anti-smooth muscle) and serum immunoglobulins, add antimitochondrial antibody in cholestatic presentations, test anti-HEV IgM in selected cases, and image the biliary tree, usually with abdominal ultrasound (GS 16). Categorize the case by R value at presentation, R = (ALT/ULN)/(ALP/ULN) (GS 15). Liver biopsy is NOT required for diagnosis but may help in severe or protracted cases, when there is diagnostic uncertainty, or when biochemistries/symptoms fail to improve after dechallenge (GS 19-20). For causality, note that the guidance does not endorse a single instrument: it describes three commonly used methods each with strengths and limitations (GS 24), observes that DILIN semiquantitative expert opinion is frequently used in practice and research but requires specialized expertise that limits generalizability (GS 26), and that updated RUCAM has better instructions but retains age, alcohol and pregnancy as risk factors of unclear value (GS 27). Management: discontinuation of the suspect drug plus supportive care, antiemetics, antipruritics, hydration, is the mainstay (GS 39). A short course of intravenous N-acetylcysteine may benefit hospitalized ADULT patients with DILI-related acute liver failure, but NAC is NOT recommended for children (GS 40); in acetaminophen overdose with established liver injury, continue NAC infusion at 6.25 mg/kg/h until ALT is falling and INR < 2. Corticosteroids for 1-3 months may benefit selected patients, severe hypersensitivity features, DRESS, immune checkpoint inhibitor injury with ALT > 5× ULN, or autoimmune-like features on biopsy, but optimal dose and duration are unknown for lack of controlled trials; typical dosing is prednisone 40-60 mg/day, or methylprednisolone-equivalent 1 mg/kg/day for checkpoint inhibitor cases (GS 41). Ursodeoxycholic acid is not established therapy but is presumably safe, and may be used at 10-15 mg/kg/day in divided doses for severe pruritus (GS 42). Because spontaneous survival in idiosyncratic DILI-related acute liver failure is only about 25%, transfer such patients EARLY to a liver transplant center (GS 36); roughly 10% of registry patients suffer ALF, transplant or death within 6 months (GS 35), with higher bilirubin and INR, lower albumin, severe necrosis or fibrosis on biopsy, comorbidity burden, and pre-existing liver disease marking increased risk (GS 38). Rechallenge with the suspect drug should generally be avoided UNLESS the anticipated benefit is high for a severe or life-threatening condition, e.g. isoniazid rechallenge causes recurrent injury in only 10% but should be attempted only in active, drug-resistant TB (GS 44). Follow liver tests to resolution: DILI persisting beyond 6-12 months (chronic DILI) occurs in 10%-20% of patients (GS 37).

American Association for the Study of Liver Diseases (AASLD), "AASLD practice guidance on drug, herbal, and dietary supplement-induced liver injury" (Fontana RJ, Liou I, Reuben A, Suzuki A, Fiel MI, Lee W, Navarro V), Hepatology, 2023 (Guidance Statement 13) · reviewed 2026-07-23 ↗
Wang T … Chen M · Liver International : Official Journal of the International Association for the Study of the Liver · IF 6.7 · PubMed ↗Permalink
← Read the whole of issue №18 Every paper GI Signals surfaces gets a page like this one. All issues